绿叶,十年27亿!

药通社
Dec 25, 2025

最近精神分裂症领域药物消息频传。就在昨日,绿叶宣布与恩华药业签署合作协议,授予后者三款抗精神病药长效针剂产品在中国大陆地区的独家商业化权利,合作期限至2035年底。绿叶授权的三款产品,具体为:瑞可妥®(注射用利培酮微球(II))、瑞百莱®(棕榈酸帕利哌酮注射液(II))和美比瑞®(棕榈酸帕利哌酮注射液)。众所周知,近些年抗精神病药物创新分子研发困难,大多企业都会优先成熟产品进行剂型改良。这三款产品...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10